Biopharmaceutical company Scinai Immunotherapeutics will host a webinar on May 7 to explore the therapeutic potential of PC111, a novel monoclonal antibody targeting rare skin disorders. The webinar, scheduled for 11:30 a.m. EST, will provide insights into the treatment's mechanism and development plans for patients with Pemphigus Vulgaris and Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN).
The event follows Scinai's recent acquisition of Pincell and a related €12 million grant application under Poland's FENG program. Company executives and panelists will discuss the unmet medical needs in these rare skin conditions and PC111's innovative approach of targeting soluble Fas ligand.
The webinar represents a significant opportunity for medical professionals, investors, and patients to understand potential advancements in treating complex autoimmune skin disorders. By focusing on a targeted antibody mechanism, Scinai aims to develop more precise and potentially more effective treatments for conditions that currently have limited therapeutic options.
